about
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsEvaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightComparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical settingDrug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Treatment of Recalcitrant Pyoderma Gangrenosum with Ulcerative Colitis by Adalimumab Injection.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.Sites of recurrence in patients following clearance of psoriasis with biologic therapy.Drug survival of biologic treatments in psoriasis: a systematic review.Moderate to severe psoriasis treatment challenges through the era of biological drugs.Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis.A revolutionary therapeutic approach for psoriasis: bispecific biological agents.Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.
P2860
Q26766567-DB3DB8D9-E40C-4B65-A2B6-55FA33FD3BD0Q33729774-4B692A14-3E74-4D57-9A5E-760FC7E4D924Q34743112-46B98DA7-9F4C-48DE-9326-A4E39F788DADQ37352347-A297C83A-7EC2-4F46-9A05-4C7B9018912BQ37740737-C5A1C746-EDF7-44BC-90D0-069AAFA57E2FQ38537167-ADF3CED1-8412-43BC-AC4D-2C1918C96B43Q38594683-35C43C5C-7A37-4775-B970-6B64885B80EFQ38664951-5DBD5C05-8358-4B32-B7B6-77A20B143047Q38673099-822C79D6-10DE-4E0B-A965-1FA90846DEB2Q38723865-D4AC2767-2DF1-43C3-8EB1-035AE77C7DDFQ38831055-6F0A86FF-D2C1-4151-9A89-BC6D4964A6A0Q38990571-12F95085-9919-49AC-9AE4-5785469BB82EQ46032182-35ABDFA4-FDDD-4029-B39E-76338DB98ADBQ46118586-93564CFE-82C3-495F-BDCD-CEA6530CAB6BQ46452013-0740EF7E-7835-4AD7-9F46-405A301B7506Q47671991-012E55D0-6ADC-4401-B231-E0585AFEA770Q51565279-9BC8584B-61F2-4339-B6FF-9A28FC11A0FCQ54422386-264FA558-E1D1-4AE3-BA1A-974116EB956BQ55119166-F258BD34-95FF-42BE-8920-4CAD2CD1B4EC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biologic fatigue in psoriasis.
@en
type
label
Biologic fatigue in psoriasis.
@en
prefLabel
Biologic fatigue in psoriasis.
@en
P2093
P2860
P1476
Biologic fatigue in psoriasis
@en
P2093
Gabrielle Brown
Mona Malakouti
Rishu Gupta
P2860
P356
10.3109/09546634.2013.826341
P50
P577
2013-08-27T00:00:00Z